Harpoon Therapeutics had a negative return on equity of 112.69% and a negative net margin of 366.46%. The company had revenue of $5.91 million during the quarter, compared to analysts’ expectations of $11.31 million. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.14). Harpoon Therapeutics ( NASDAQ:HARP – Get Rating) last released its quarterly earnings results on Thursday, May 12th. The firm has a market capitalization of $83.36 million, a P/E ratio of -1.09 and a beta of 1.46. Harpoon Therapeutics has a 12 month low of $1.73 and a 12 month high of $13.20. The firm has a 50 day moving average of $2.18 and a 200-day moving average of $3.81. Hedge funds and other institutional investors own 81.07% of the company’s stock. acquired a new position in shares of Harpoon Therapeutics during the 4th quarter worth approximately $980,000. Renaissance Technologies LLC now owns 211,200 shares of the company’s stock worth $1,050,000 after buying an additional 159,600 shares during the period. Renaissance Technologies LLC raised its stake in shares of Harpoon Therapeutics by 309.3% during the 1st quarter. Tekla Capital Management LLC acquired a new position in shares of Harpoon Therapeutics during the 1st quarter worth approximately $1,292,000.
now owns 809,568 shares of the company’s stock valued at $6,112,000 after acquiring an additional 320,054 shares during the period. lifted its holdings in Harpoon Therapeutics by 65.4% in the fourth quarter. purchased a new stake in shares of Harpoon Therapeutics during the fourth quarter worth about $4,908,000. Several institutional investors and hedge funds have recently added to or reduced their stakes in HARP. Hedge Funds Weigh In On Harpoon Therapeutics Finally, Roth Capital upped their target price on shares of Harpoon Therapeutics from $14.00 to $18.00 in a research note on Tuesday, May 17th. Canaccord Genuity Group reissued a “buy” rating and set a $16.00 price objective on shares of Harpoon Therapeutics in a research report on Wednesday, July 6th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Harpoon Therapeutics in a research report on Monday, May 9th. Canaccord Genuity Group decreased their price objective on shares of Harpoon Therapeutics from $30.00 to $14.00 in a report on Wednesday, March 23rd. Wedbush upped their price target on shares of Harpoon Therapeutics from $5.00 to $7.00 and gave the company an “outperform” rating in a report on Monday, May 16th. HARP has been the subject of a number of recent analyst reports. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $12.89. Five equities research analysts have rated the stock with a buy recommendation. ( NASDAQ:HARP – Get Rating) has received a consensus rating of “Buy” from the ten research firms that are covering the company, reports.